Literature DB >> 2323120

Clinical approach to paroxysmal atrial fibrillation.

P Coumel1.   

Abstract

In addition to the role of the electrophysiological substrate, paroxysmal atrial fibrillation depends on the modulation of the atrial tissues by the autonomic nervous system. Experimentally, models of atrial fibrillation can be based on either adrenergic or vagal stimulations that provoke the arrhythmia by disturbing in a different way conduction and refractory periods of the atrium. Clinically, the role of the autonomic nervous system can be suspected from the clinical history, and paroxysmal attacks can typically be observed either at daytime or at night, at exercise or at rest. Careful attention should be paid to the changes of heart rate that occur in the minutes or tens of minutes prior to the attacks, and the trend of acceleration or slowing of cardiac frequency observed in Holter tracings provides reliable indications of the state of the vago-sympathetic balance in these patients. During the attacks, the electrocardiographic aspect of atrial flutter alternating with a pattern of atrial fibrillation is typical of vagally dependent arrhythmias, whereas atrial tachycardia is more frequently observed at the onset of adrenergic atrial fibrillation. When the paroxysmal forms of arrhythmia are resistant to usual pure antiarrhythmic therapy including type IA agents and flecainide or encainide, one should take into account the role of the autonomic nervous system. Propafenone, or beta-blockers combined with type I drugs, are very effective every time an adrenergic factor is involved, but prevent the beneficial role of other agents if a vagal mechanism is predominant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2323120     DOI: 10.1002/clc.4960130311

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  Autonomic modulation of the atrial cycle length by the head up tilt test: non-invasive evaluation in patients with chronic atrial fibrillation.

Authors:  M P Ingemansson; M Holm; S B Olsson
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

2.  Management of Atrial Fibrillation: Identifying and treating the causes.

Authors:  S W Rabkin
Journal:  Can Fam Physician       Date:  1991-03       Impact factor: 3.275

3.  Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature.

Authors:  Pattara Rattanawong; Jakrin Kewcharoen; Komandoor S Srivathsan; Win-Kuang Shen
Journal:  J Atr Fibrillation       Date:  2020-06-30

Review 4.  Palpitations: a proper evaluation and approach to effective medical therapy.

Authors:  Christopher C Pickett; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

Review 5.  Renal Denervation And Pulmonary Vein Isolation In Patients With Drug Resistant Hypertension And Symptomatic Atrial Fibrillation.

Authors:  Scott Wilson; Peter Kistler; Alex J McLellan; Dagmara Hering; Markus P Schlaich
Journal:  J Atr Fibrillation       Date:  2014-12-31

6.  Assessment of the effect of left atrial cryoablation enhanced by ganglionated plexi ablation in the treatment of atrial fibrillation in patients undergoing open heart surgery.

Authors:  Jiří Bárta; Radim Brát
Journal:  J Cardiothorac Surg       Date:  2017-08-17       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.